BioProduction by Sekisui describes Sekisui’s contract service offering as a fermentation focused CDMO with expertise in enzymes and downstream purification. Our microbial process development and production experience helps smooth technical transfer and process scale up. Our core competencies include E. coli and yeast fermentation, plant tissue extraction, large scale bioprocessing, protein purification, bulk formulation, lyophilization and analytical testing.
As part of Sekisui Diagnostics, our production site in the UK has been a leader in the manufacturing of high-quality enzymes and specialty biochemicals to the global healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including enzymes for biotherapeutic manufacture, pharmaceutical production, diagnostic reagents, biosensors and medical devices.
Sekisui Diagnostics is part of the Sekisui Chemical Co. Ltd. family, and a sister company to Sekisui Medical. Backed by the resources of our global parent, we remain focused on contributing to the realization of healthy and enriched lifestyles for all people.
Headquartered in Burlington, MA, USA, Sekisui Diagnostics has annual revenue of $200 million and more than 450 employees worldwide. Our R&D and manufacturing facilities are located internationally on two different continents while our long tenured sales & service staff concentrates on building strong partnerships with our customers across the globe.
Sekisui Medical – Pharmaceuticals
Through another SEKISUI Medical Group subsidiary, we can offer services in active pharmaceutical ingredient (API) manufacturing. Sekisui XenoTech’s global team utilizes our expertise in optical resolution for amino acid production to provide GMP-compliant, FDA/JP/EDQM-inspected, contract manufacturing of new investigational drugs, active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.
Our multi-purpose cGMP facility is capable of both water-based and organic solvent-based manufacturing to meet any reaction and treatment needs with quality assurance testing and cutting-edge equipment. Our Research & Development team can quickly and consistently support manufacturing of grams to couple of kilograms, pilot-scale manufacturing, up to industrial-scale manufacturing.
SEKISUI XenoTech is a specialty global Contract Research Organization (CRO) specializing in ADME/DMPK/DDI testing on potential drug candidates. Utilized by top pharma, universities, biotech companies, and numerous other organizations, SEKISUI XenoTech provides the finest tools and resources to advance the development of effective, safe drugs.
As a drug metabolism and drug-drug interactions (DDI) experts, SEKISUI XenoTech boasts more than 25 years of supporting drug developers to evaluate their compounds for pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME) and drug-drug interaction (DDI) potential. Services span in vivo and in vitro contracted studies, and products such as cryoplateable hepatocytes and subcellular fractions are available to drug developers worldwide to ensure top quality test systems for their in-house assays.
Equipped with data from pharmacokinetic studies, drug developers can bring safe, effective therapeutics to market faster. Early in vitro data to develop a drug compound’s pharmacokinetic profile can support confident, informed, risk-based decision making early on in a compound’s development, potentially mitigating serious setbacks later in the pipeline. To learn more about how you can use in vitro and in vivo ADME/PK and DDI studies to bolster your drug compound’s chance of success, visit xenotech.com